Health Economics›Renal cell carcinoma›Metastatic disease, third-line

Metastatic disease, third-line

Renal cell carcinoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Sorafenib monotherapy Variant #04	—	R 37 339	28d	3.9 mo	—	5	R 186 694 PFS proxy	1
Tivozanib monotherapy Variant #01 Partial	—	—	28d	~7.4 mo	—	~9	—	3

2 of 2 regimens shown